AbbVie Inc.

关键催化剂

• Skyrizi and Rinvoq growth

  Continued Skyrizi and Rinvoq adoption is expanding AbbVie's immunology portfolio and replacing revenue lost after Humira's U.S. exclusivity expiry.

• Neuroscience momentum

  Growth across Vraylar, Botox Therapeutic, the migraine portfolio, and Vyalev broadens AbbVie's growth base beyond immunology.

• Pipeline milestones

  Regulatory submissions, approvals, and key clinical data readouts expected over the next year could add indications and reinforce the post-Humira portfolio transition.

主要风险

• Humira erosion

  Humira revenue continues to contract after biosimilar entry, leaving execution on replacement growth products essential to the portfolio transition.

• Oncology portfolio pressure

  Imbruvica declines are weighing on oncology, requiring growth from Venclexta, Elahere, and pipeline assets to offset the mature brand.

• Government pricing exposure

  U.S. drug-pricing policy, including the selection of Botox for Medicare negotiated prices beginning in 2028, could pressure future revenue and margins.

For the quarter ended March 31, 2026, AbbVie reported broad revenue growth led by immunology and neuroscience, while Humira and Imbruvica declines remained portfolio headwinds; management raised its full-year adjusted EPS guidance.

估值解读

• A stronger valuation case depends on Skyrizi, Rinvoq, and neuroscience growth continuing to more than offset mature-brand erosion.
• Pipeline execution can support a durable growth premium, while drug-pricing exposure and concentration in key products warrant an uncertainty discount.